Replimune, Inc.
Clinical trials sponsored by Replimune, Inc., explained in plain language.
-
New hope for rare eye cancer: experimental combo enters late-stage trial
Disease control Recruiting nowThis study tests whether a new drug called RP2, given with nivolumab, works better than the standard combination of ipilimumab and nivolumab for people with metastatic uveal melanoma—a rare eye cancer that has spread. About 280 adults who have not had prior immunotherapy will rec…
Phase: PHASE2, PHASE3 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New hope for advanced melanoma patients who failed standard therapies
Disease control Recruiting nowThis study tests whether a new drug (vusolimogene oderparepvec) combined with nivolumab works better than standard treatments for people with advanced melanoma that has stopped responding to prior immunotherapy. About 400 participants will be randomly assigned to receive either t…
Phase: PHASE3 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Cancer-fighting virus shows promise in liver cancer trial
Disease control Recruiting nowThis study tests a new treatment called RP2, a virus that attacks cancer cells, combined with standard drugs for people with advanced liver cancer or bile duct cancer that has not responded to first treatment. About 60 adults will take part. The goal is to see if the combination …
Phase: PHASE2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Researchers track Long-Term risks of viral cancer therapy
Knowledge-focused Recruiting nowThis study watches 50 people who already received a replimune oncolytic immunotherapy for cancers like melanoma or liver cancer. The goal is to check for any delayed side effects over 5 years. No new treatment is given—just regular check-ins to see how patients are doing.
Sponsor: Replimune, Inc. • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:08 UTC